Enterprise Value
8.728M
Cash
21.22M
Avg Qtr Burn
-8.349M
Short % of Float
2.66%
Insider Ownership
0.41%
Institutional Own.
20.37%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Maveropepimut-S (DPX-Survivac) (Survivin) + CPA Details Ovarian cancer, Cancer | Phase 2b Data readout | |
Maveropepimut-S (DPX-Survivac) (Survivin) + Keytruda + CPA Details Diffuse large B cell lymphoma, Cancer | Phase 2b Update | |
Maveropepimut-S (DPX-Survivac) (Survivin) + CPA + Pemrolizumab Details Ovarian cancer, Cancer | Phase 2 Update | |
Maveropepimut-S (DPX-Survivac) (Survivin) Details Cancer, Solid tumor/s, Breast cancer | Phase 1b Data readout | |
DPX-RSV Details Respiratory syncytial virus | Failed Discontinued | |
Maveropepimut-S (DPX-Survivac) (Survivin) + CPA + Keytruda Details Ovarian cancer, Bladder cancer, Liver cancer, Cancer | Failed Discontinued | |
DPX-COVID-19 Details COVID-19 | Failed Discontinued |